Welcome to our dedicated page for BioNxt Solutions news (Ticker: $BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioNxt Solutions's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioNxt Solutions's position in the market.
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) settles $2,581,096 in convertible debentures and interest with an arm's length creditor by issuing common shares and an unsecured convertible debenture. The settlement terms include a conversion price of $0.50 per share, a maturity date of one year, and an 8% annual interest rate. Canaccord Genuity Corp. acted as the advisor in connection with the settlement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) provides details on its clinical and commercialization strategy for its 100% Cladribine IP acquisition. The company is focusing on developing a proprietary oral dissolvable film (ODF) based Cladribine product for the treatment of Multiple Sclerosis (MS). Preclinical work is underway, and GMP product development and batch production are planned for 2024. The company aims to capitalize on the growing Cladribine tablet market, with potential advantages for an ODF product. The market for MS drugs is expected to reach over US$41 billion by 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. (BNXT) provides details on its 100% Cladribine IP acquisition and development program for a proprietary oral dissolvable film (ODF) based Cladribine product for the treatment of Multiple Sclerosis (MS). Cladribine, previously used for leukemia, has seen significant sales growth in the MS market. BioNxt's ODF formulation aims to offer advantages over conventional tablet forms, including instant dissolution and potential dosing precision. The company plans human bioequivalence studies for 2024 and has filed preliminary patent applications for Cladribine ODF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BioNxt Solutions Inc. (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) signs a definitive agreement with a German-based pharmaceutical developer for the acquisition of 100% of the intellectual property rights and joint development of an oral dissolvable drug reformulation using the active pharmaceutical ingredient Cladribine. Cladribine is approved for use in over 75 countries for treating highly active forms of relapsing-remitting Multiple Sclerosis and certain forms of leukemia. The global Multiple Sclerosis drug market is expected to exceed US$ 41 Billion by 2033 according to Market.us. BioNxt aims to participate in this growing market with a proprietary dosage form based on its drug delivery platform, focusing on the Cladribine ODF and Rotigotine TDS development programs as priority initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. reports on a successful CPHI pharma conference in Barcelona, Spain. The conference had over 45,000 attendees and 1,500 exhibitors from over 150 countries. BioNxt's team was invited by major pharmaceutical companies to discuss projects related to its transdermal patch and oral dissolvable drug delivery platforms. Potential partners expressed interest in continued negotiations on potential cooperation terms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
BioNxt Solutions Inc. has closed the final tranche of its non-brokered private placement, raising $543,250 in gross proceeds. The total placement size was $2,000,750. The company plans to use the funds for research, development, and commercialization activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BioNxt Solutions Inc. announces resignations of Per Thoresen and Peter Damouni as directors. Joseph Meagher appointed as a director to fill one vacancy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioNxt Solutions Inc. has closed the second tranche of its private placement, raising $662,500. The total placement size is expected to be a maximum of $3,975,000. The company plans to use the funds for research, development, and commercialization activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BioNxt Solutions Inc. has signed a non-binding letter of intent with two European-based parties to acquire 100% of the intellectual property rights and co-develop an oral dissolvable film drug reformulation. The reformulation will incorporate an active pharmaceutical ingredient approved by the FDA and EMA for multiple indications, including the treatment of a major neurodegenerative disease. The consideration for the acquisition and co-development includes Euro 150,000 cash and 2,600,000 common shares based on milestone targets. Sales of the primary name-brand product based on a tablet form of the approved API grew organically by over 15% in 2022, reaching global sales exceeding Euro 850 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.24%
Tags
BioNxt Solutions Inc.
OTC:BNXTF
BNXTF Rankings
BNXTF Stock Data
36.85M
99.31M
6.26%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Vancouver